Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response

BACKGROUND: Minimally invasive radiofrequency ablation (RFA) is used as a first-line treatment option for hepatocellular cancer (HCC) with the weaknesses of incomplete ablation, tumor recurrence, and inferior outcomes. To overcome this limitation, we proposed to develop sunitinib-RFA integrated ther...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunother Cancer
Autori principali: Qi, Xiaoqiang, Yang, Ming, Ma, Lixin, Sauer, Madeline, Avella, Diego, Kaifi, Jussuf T, Bryan, Jeffrey, Cheng, Kun, Staveley-O’Carroll, Kevin F, Kimchi, Eric T, Li, Guangfu
Natura: Artigo
Lingua:Inglês
Pubblicazione: BMJ Publishing Group 2020
Soggetti:
Clinical/Translational Cancer Immunotherapy
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594543/
https://ncbi.nlm.nih.gov/pubmed/33115942
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001038
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi